An innovative cell analytics technology that can increase therapy manufacturing efficiency by 30% and therefore reduce costs for up to 400K UK patients per year

Cytomos是一家英国生物技术中小企业，核心项目团队为林赛弗雷泽（CSO，研究/项目经理负责人），Gordon Sharp（仪器开发部CTO），Tom克莱顿（首席系统架构师，固件/软件开发）和Sevi Giakoumelou（项目和研究经理，研究开发）。遗传疾病和罕见疾病的细胞疗法的成本可能是惊人的，从4万英镑到远远超过100万英镑，有些治疗会持续一辈子这种水平的费用可能使某些人群无法获得医疗服务，并迫切需要更有效的细胞和基因疗法，以确保个性化医疗不受社会经济因素的限制。英国是世界上超过12%的细胞和基因治疗临床试验的所在地，为了提高效率，英国的生物制造技术路线图要求到2030年将制造成本降低90%，时间缩短80%。现有的细胞治疗制造工艺使用的技术在制造过程中不直接观察细胞，因此返回的信息有限。为了创造更有效的分析，Cytomos正在开发一种技术，可以查看单个细胞的细节，利用电场创建一种无标签、可扩展的解决方案，具有自动化潜力，每年可以使多达40万英国患者受益，解决医疗保健不平等问题。Cytomos的项目将使细胞疗法制造效率提高30%，并将患者成本降低20%。简化的制造过程将减少对环境的影响，并进一步提高对患者的可用性。

Cytomos is a UK biotechnology SME with a core project team of Lindsay Fraser (CSO, Head of Research/Programme Manager), Gordon Sharp (CTO, Instrument Development), Tom Clayton (Lead System Architect, Firmware/Software Development) and Sevi Giakoumelou (Project and Research Manager, Research Development).The cost of cell therapy for genetic disorders and rare diseases can be staggering, ranging from £40K to well over £1M, with some treatments continuing for a lifetime. This level of expense can put care out of reach for some populations and has created an immediate and urgent need for more efficient cell and gene therapies to ensure that personalised medicine is not limited by socioeconomic factors. The UK is home to over 12% of the world's clinical trials for cell and gene therapy, and to increase efficiency, the UK's Biomanufacturing Technology Roadmap calls for a 90% reduction in manufacturing costs and an 80% reduction in time by 2030\.Existing cell therapy manufacturing processes use techniques that do not look directly at the cells during manufacture and thus return limited information. To create more effective analytics, Cytomos is developing technology that looks at the details of an individual cell, using electrical fields to create a label-free, scalable solution with automation potential that could benefit up to 400K UK patients per year, addressing healthcare inequality.Cytomos' project will increase cell therapy manufacturing efficiency by 30% and reduce patient costs by up to 20%. A streamlined manufacturing process will reduce environmental impact and further improve availability to patients.